Vensana Capital is a venture capital and private equity firm that specializes in investing in medical technology companies. The firm focuses on providing capital and strategic support to innovative startups and emerging companies in the healthcare sector that are developing transformative medical technologies.

Vensana Capital is a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology.
 
Launched in 2019 by Kirk Nielsen and Justin Klein, Vensana is actively investing in late development and commercial stage companies across the medtech sector, including medical devices, diagnostics, drug delivery, digital health, and tech-enabled services.

CVRx

Vesper Medical

Personal Genome Diagnostics

Intact Vascular

Vensana Capital

Vensana Capital is looking to expand it's team!

🎙️—> Had a great time in this  podcast with host Geoff Pardo, one of the best investors in our sector and consistently a great partner to our companies at Vensana Capital 💪


#medtechtalk

One of our most interesting #medtech panels yet is taking place now at #InnovationSF23: Understanding Investment Strategies Across the Spectrum with:

Ajay Dharia, Venture Partner, MedTech Venture Partners
Shawn Fu, M.D., Vice President, Vertex Ventures HC
Greg Garfield, Senior Managing Director, KCK Medtech
Dave Hood, President & CEO, DH3 Associates
Cynthia Yee, Principal, Vensana Capital
David Cassak, Editor-in-Chief, MedTech Strategist (moderator)

What the CEOs read:
bit.ly/3QvOw6I

Vensana Capital is one of the few medtech venture funds that invests across the spectrum of development from inception to early commercial growth. Excited to share how we approach investing at different stages in the start-up lifecycle. 

Hint: one strategy doesn't fit all and this is where critical thinking in addition to relationships, market momentum and luck come into play.

Thanks to the strong team work from the innovative problem solvers at SpyGlass Pharma, Inc. More than a few 12hr+ days, missed vacations and tens of millions of dollars... and we're one step closer! 
#Ophthalmology #CataractSurgey  #Glaucoma #Migs #AAO2023 #ASCRS 

Vensana Capital 
New Enterprise Associates (NEA) 
 RA Capital Management

Fantastic results from Vesper Medical, Inc.  Duo Venous Stent presented today at #TheVeins23 Late-Breaking Clinical Trials Session. Best-in-class 12-month primary patency of 90.2% with ZERO stent fractures or migration.  

Thanks to Dr. Mahmood Razavi, principal investigator of the #VIVID pivotal clinical study, and all the physicians who contributed helping bring this therapy to patients.  

Our team at Vensana Capital is proud to have supported this program since its inception and to continue partnering with pioneering innvovators in the peripheral vascular sector. And of course, this wouldn't have been possible without the team at Vesper Medical, Inc. , and Philips: Bruce S., Mike Longo, Marc Penna, Joseph C. Griffin, III, Mark Garcia and Justin Klein, MD, JD.

Thrilled with this ⭐️ all-star ⭐️ group of innovators in peripheral vascular disease. Their guidance and support has been essential in our effort to develop a best-in-class imaging platform for vascular intervention. 

More great things to come!

Congrats to the entire team at Volta Medical on winning this year’s #prixgalien 🥇for Best Startup!

This team is so committed to bringing innovation to patients suffering from the burden of atrial fibrillation 🫀. We’re proud Vensana Capital in their partner in a brilliant application of artificial intelligence to a major unmet medical need. 👏👏👏

More to come!

COM:VENSANACAP

Vensana Capital

Analysis Not Available